Study finds that AREDS 2 supplementation helps slow progression of late-stage macular degeneration
AMD

Study finds that AREDS 2 supplementation helps slow progression of late-stage macular degeneration

While researchers have known that AREDS 2 supplements help slow the progression of AMD from the intermediate stage to the late stage, they wanted to establish whether supplementation could impact t...
Retrospective study suggests melatonin may decrease risk development of macular degeneration
age-related macular degeneration

Retrospective study suggests melatonin may decrease risk development of macular degeneration

Melatonin has antioxidant properties and researchers sought to discover if it might provide benefits for eye health.
Low-dose aspirin offers no benefit against macular degeneration
age-related macular degeneration

Low-dose aspirin offers no benefit against macular degeneration

Australian researchers recently published the results of a study that examined the effects of low-dose aspirin on age-related macular degeneration.
Study shines light on Saffron's positive affects on vision
age-related macular degeneration

Study shines light on Saffron's positive affects on vision

Despite it's hefty price tag, saffron, which is a powerful antioxidant, is a popular dietary supplement used for a wide range of ailments including the improvement of cognitive function, mood boost...
Visual hallucinations commonly associated with age-related macular degeneration
age related macular degeneration

Visual hallucinations commonly associated with age-related macular degeneration

Charles Bonnet Syndrome (CBS) is a condition that occurs when people lose some or all of their vision.
FDA approves Izervay for treatment of geographic atrophy
AMD

FDA approves Izervay for treatment of geographic atrophy

The Food and Drug Administration (FDA) recently announced their approval of Izervay for treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
AMD patients with visual disability at higher risk of cardiovascular disease
age related macular degeneration

AMD patients with visual disability at higher risk of cardiovascular disease

Researchers at Sungkyunkwan University School of Medicine in Korea conducted a nationwide cohort study involving nearly 4 million adults.
FDA approves first drug to treat geographic atrophy
age-related macular degeneration

FDA approves first drug to treat geographic atrophy

Geographic atrophy typically affects people over the age of 50 and is one of the main causes of vision loss in the United States.
Potential cause of AMD identified
age-related macular degeneration

Potential cause of AMD identified

Researchers discovered a rare genetic variant that generates malformed proteins that change the stability of the membrane attack complex (MAC).